Oncolytic Virus Therapy Market Fueled by Immuno-Oncology Advancements and Clinical Trial Momentum | Amgen, Shanghai Sunway Biotech Co. Ltd, and RIGVIR

The global oncolytic virus therapy market reached US$ 38.27 million in 2023 and is expected to reach US$ 146.20 million by 2031, growing at a CAGR of 18.5% during the forecast period 2024-2031.

Oncolytic Virus Therapy Market Report by DataM Intelligence offers a detailed assessment of the global pharmaceutical and healthcare landscape, highlighting market size, key players, and critical growth drivers. With growing focus on immuno-oncology, expanding clinical trials, and the potential of virus-based cancer therapies, the report delivers strategic insights for stakeholders in the next-generation cancer therapeutics space from 2025 to 2033.

Download exclusive insights with our detailed sample report (Corporate Email ID gets priority access): https://www.datamintelligence.com/download-sample/oncolytic-virus-therapy-market?ophp

Oncolytic virus therapy uses genetically modified viruses to infect and destroy cancer cells while stimulating the immune system to recognize tumors. This innovative cancer immunotherapy approach is gaining momentum, with multiple candidates in clinical trials and growing interest from biotech firms. The market is projected to grow significantly, driven by rising cancer incidence, FDA designations, and strategic collaborations in oncology R&D.

Oncolytic Virus Therapy Market Competitors Overview:

Amgen, Shanghai Sunway Biotech Co. Ltd, and RIGVIR.

Important Industry Updates of 2023, 2024 and 2025:

✅ Philips launched the Zenition 10 mobile C‐arm with flat-panel technology and real‐time AI-based enhancements in 2023-24, and rolled out upgrades to support high-volume US hospital usage in 2025

✅ CG Oncology is running Phase III trials of cretostimogene grenadenorepvec in BCG-unresponsive non‐muscle invasive bladder cancer (NMIBC), with FDA Fast Track and Breakthrough Therapy designations already granted

✅ Genelux's Olvi‐Vec candidate is being deployed in Phase III studies for platinum‐resistant ovarian cancer, as well as Phase II trials in NSCLC; it also has FDA Fast Track status

✅ UP Oncolytics, a Milwaukee-based spinout, received an NIH SBIR grant plus a $75,000 state development matching award in mid‐2025 to advance its glioma-targeted oncolytic virus, which received FDA Orphan Drug Designation in late 2024

✅ In 2025, Transgene SA (France) continues co-developing its Invir.IO oncolytic viruses with AstraZeneca, leveraging programmable vaccinia-based platforms for tumor-selective expression of immunomodulatory agents

Methodology and Scope

The Oncolytic Virus Therapy Market Report is built on a rigorous research methodology that integrates primary interviews, expert insights, and validated secondary data from company reports, industry publications, and reliable databases. Utilizing both bottom-up and top-down approaches, the analysis ensures high data accuracy through triangulation. The report covers current market dynamics, growth opportunities, and key strategic developments across global and regional markets.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/oncolytic-virus-therapy-market?ophp

Oncolytic Virus Therapy Market Segments Overview:

∎ By Drug Class (Onxy-15, Talimogene laherparepvec, Reolysin, RIGVIR, Others)
∎ By Application (Melanoma, Ovarian Cancer, Breast Cancer, Others)
∎ By Therapy Type (HSV-based Oncolytic Viruses, Adenoviruses-based Oncolytic Viruses, Vaccinia virus-based Oncolytic Viruses, Vesicular Stomatitis Virus-based Oncolytic Viruses, Newcastle Disease Virus-based Oncolytic Viruses)

The monotherapy segment is currently dominant, as many therapies in clinical trials or early approvals are being developed as standalone treatments to selectively kill tumor cells.

Regional Overview for Oncolytic Virus Therapy Market:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

North America holds the largest share of the oncolytic virus therapy market, led by cutting-edge research, clinical trials, and FDA support. Asia Pacific is the fastest growing region, with growing cancer incidence and increased investment in immunotherapy research and clinical collaborations.

Looking for in-depth insights? Grab the full report: https://www.datamintelligence.com/customize/oncolytic-virus-therapy-market?ophp?ophp

The Report Covers:

➡ In-depth analysis of the demand-supply gap, market size estimates, SWOT and PESTEL analysis, along with global market forecasts.
➡ Strategic recommendations with a focused go-to-market approach.
➡ An unbiased evaluation of overall market performance.
➡ Region- and country-specific insights, with customized reports available upon request.
➡ Identification of high-potential and niche segments and regions demonstrating strong growth prospects.

People Also Ask:

➤ What are the current global trends in sales, production, imports, and exports within the Oncolytic Virus Therapy market?
➤ Who are the leading manufacturers, and what are their production volumes, pricing strategies, and revenue metrics?
➤ What are the major opportunities and challenges facing vendors in this market?
➤ Which product categories, applications, or end-user segments are contributing most to market growth and share?
➤ What are the primary factors driving and restraining growth in the Oncolytic Virus Therapy market?

Unlock 360° Market Intelligence with 2 Days FREE Trial Access of DataM Subscription Now!: https://www.datamintelligence.com/reports-subscription?ophp

✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drugs Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.